This event is archived. Final snapshot from when the story concluded. View on Dashboard
Business Initial Public Offering

Medtronic MiniMed IPO Priced at $20

Analysis based on 10 articles · First reported Feb 24, 2026 · Last updated Mar 06, 2026

Sentiment
60
Attention
4
Articles
10
Market Impact
Direct
Live prominence charts, article sentiment distribution, and event development timeline available on the NewsDesk Dashboard

The IPO of Medtronic===Medtronic MiniMed is expected to generate significant interest in the medical device and healthcare sectors, potentially leading to increased investment in diabetes management technologies. For Medtronic, this spin-off allows it to unlock value from its diabetes unit while maintaining a substantial ownership stake, which could positively impact its stock performance.

Medical Devices Healthcare Financial Services

Medtronic===Medtronic MiniMed, a subsidiary of Medtronic, has priced its initial public offering (IPO) of 28 million shares at $20.00 per share, aiming to raise $560 million. The shares are set to begin trading on the Nasdaq Global Select Market on March 6, 2026, under the ticker symbol 'MMED'. Medtronic will retain approximately 90.03% ownership of Medtronic===Medtronic MiniMed post-IPO. The proceeds from the offering will be used for general corporate purposes, to repay intercompany debt owed to Medtronic, and as additional consideration for assets transferred during the separation. Goldman Sachs, BofA Securities, Citigroup, and Morgan Stanley are leading the offering as active bookrunners, supported by several other financial institutions.

100 Medtronic===Medtronic MiniMed priced initial public offering
90 Medtronic===Medtronic MiniMed will begin trading on Nasdaq Nasdaq
80 Medtronic===Medtronic MiniMed granted underwriters option to purchase additional shares
60 Goldman Sachs acted as active bookrunner for IPO Medtronic===Medtronic MiniMed
60 Citigroup acted as active bookrunner for IPO Medtronic===Medtronic MiniMed
60 Morgan Stanley acted as active bookrunner for IPO Medtronic===Medtronic MiniMed
subs
Medtronic===Medtronic MiniMed is conducting its initial public offering, pricing 28 million shares at $20.00 each, aiming to raise $560 million. This IPO will allow Medtronic===Medtronic MiniMed to become a publicly traded company, with its shares trading on the Nasdaq Global Select Market under the symbol 'MMED'.
Importance 100 Sentiment 70
stock
Medtronic, as the parent company, is spinning off its Medtronic===Medtronic MiniMed subsidiary through an IPO. Medtronic is expected to retain approximately 90.03% of Medtronic===Medtronic MiniMed after the offering, or 88.70% if the underwriters exercise their over-allotment option in full. This move allows Medtronic to monetize a portion of its diabetes unit while maintaining a significant stake.
Importance 90 Sentiment 50
stock
Goldman Sachs & Co. LLC is acting as an active bookrunner for the Medtronic===Medtronic MiniMed IPO, playing a significant role in facilitating the offering.
Importance 60 Sentiment 30
subs
BofA Securities is acting as an active bookrunner for the Medtronic===Medtronic MiniMed IPO, contributing to the successful execution of the offering.
Importance 60 Sentiment 30
stock
Citigroup is acting as an active bookrunner for the Medtronic===Medtronic MiniMed IPO, assisting in the management and distribution of the shares.
Importance 60 Sentiment 30
stock
Morgan Stanley & Co. LLC is acting as an active bookrunner for the Medtronic===Medtronic MiniMed IPO, providing essential services for the offering.
Importance 60 Sentiment 30
exch
The Nasdaq Global Select Market will be the exchange where Medtronic===Medtronic MiniMed shares will begin trading under the symbol 'MMED'. This adds a new company to its listed entities.
Importance 40 Sentiment 20
+ 9 more entities View on Dashboard
NEWSDESK
Track this event live

Set up alerts, explore entity relationships, search across thousands of events, and build custom intelligence feeds.

Open Dashboard

About NewsDesk

NewsDesk is a news intelligence platform that converts raw news articles into structured data. It tracks events, entities, and the relationships between them, with sentiment and attention metrics derived from thousands of articles. Pages on this site are daily static snapshots from the platform's live database. For real-time tracking, search, and alerts, the full dashboard is at app.newsdesk.dev.